JPS5973515A - 肝障害抑制剤 - Google Patents
肝障害抑制剤Info
- Publication number
- JPS5973515A JPS5973515A JP57185026A JP18502682A JPS5973515A JP S5973515 A JPS5973515 A JP S5973515A JP 57185026 A JP57185026 A JP 57185026A JP 18502682 A JP18502682 A JP 18502682A JP S5973515 A JPS5973515 A JP S5973515A
- Authority
- JP
- Japan
- Prior art keywords
- acetyl
- compound
- active component
- benzyloxycarbonyl
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000019423 liver disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 9
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims abstract description 5
- 206010067125 Liver injury Diseases 0.000 claims description 12
- 231100000234 hepatic damage Toxicity 0.000 claims description 12
- 230000008818 liver damage Effects 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 abstract description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 5
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 235000019325 ethyl cellulose Nutrition 0.000 abstract description 5
- 229920001249 ethyl cellulose Polymers 0.000 abstract description 5
- 239000008101 lactose Substances 0.000 abstract description 5
- NMTZPYLSXWGDPW-UHFFFAOYSA-N 3-amino-n-(2-sulfanylethyl)propanamide Chemical compound NCCC(=O)NCCS NMTZPYLSXWGDPW-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000011230 binding agent Substances 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 2
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 3
- 229960000903 pantethine Drugs 0.000 description 3
- 235000008975 pantethine Nutrition 0.000 description 3
- 239000011581 pantethine Substances 0.000 description 3
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- DDDVINJUMQBWAD-UHFFFAOYSA-N s-[2-(3-acetamidopropanoylamino)ethyl] ethanethioate Chemical compound CC(=O)NCCC(=O)NCCSC(C)=O DDDVINJUMQBWAD-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57185026A JPS5973515A (ja) | 1982-10-20 | 1982-10-20 | 肝障害抑制剤 |
| US06/488,100 US4552765A (en) | 1982-05-14 | 1983-04-25 | Aletheine derivatives |
| IT21040/83A IT1164218B (it) | 1982-05-14 | 1983-05-11 | Derivati della aleteina |
| GB08313145A GB2123815B (en) | 1982-05-14 | 1983-05-12 | Aletheine derivatives |
| DE3317529A DE3317529C2 (de) | 1982-05-14 | 1983-05-13 | ß-Aletheinderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| FR8308048A FR2526792B1 (fr) | 1982-05-14 | 1983-05-16 | Derives d'aletheine utiles pour le traitement des lesions hepatiques |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57185026A JPS5973515A (ja) | 1982-10-20 | 1982-10-20 | 肝障害抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5973515A true JPS5973515A (ja) | 1984-04-25 |
| JPH0224248B2 JPH0224248B2 (enExample) | 1990-05-29 |
Family
ID=16163478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57185026A Granted JPS5973515A (ja) | 1982-05-14 | 1982-10-20 | 肝障害抑制剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5973515A (enExample) |
-
1982
- 1982-10-20 JP JP57185026A patent/JPS5973515A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0224248B2 (enExample) | 1990-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4929605A (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
| PT1302461E (pt) | Inibidores de produção de tnf-alpha | |
| JPH05501540A (ja) | Ｐｃｐレセプター・リガンドおよびその用途 | |
| US5220068A (en) | Psychostimulant agent | |
| CN111635315B (zh) | 一种解热镇痛药物及其制备方法和用途 | |
| DE69931814T2 (de) | Umwandlung von cox-inhibierenden, nicht cox-2 selektiven inhibitoren in derivate von cox-2 selektiven inhibitoren | |
| CA1120400A (en) | Method of treating hypertension and medicaments therefor | |
| US4514420A (en) | Antifibrotic agent | |
| JP2930281B2 (ja) | 皮膚疾患処置用薬剤 | |
| BRPI0615046B1 (pt) | uso de um composto | |
| WO2007125196A1 (fr) | Composés de type 1, 4-naphtoquinones, compositions les comprenant et utilisation de ces composés en tant qu'agents anti -cancéreux | |
| AU765476B2 (en) | Cyclooxygenase inhibitor | |
| JPS615017A (ja) | 抗潰瘍組成物 | |
| JPH0352816A (ja) | 腎炎の治療剤 | |
| JPS5973515A (ja) | 肝障害抑制剤 | |
| US3462534A (en) | Production of an antidepressant effect with esters of gallic acid | |
| JPS61155327A (ja) | ジヒドロピリジン化合物を含有する抗動脈硬化剤 | |
| AU657412B2 (en) | Agent for increasing somatostatin or for inhibiting decrease of somatostatin | |
| JP2681085B2 (ja) | 胃炎治療剤 | |
| JP3090211B2 (ja) | 第４級ｎ−ベンジル−ｎ−｛２−〔２−（（１ｓ，５ｓ）−６，６−ジメチルビシクロ〔３．１．１〕−ヘプト−２−イル）エトキシ〕エチル｝モルホリニウム塩を含有する胃保護作用を有する製薬学的調剤およびその製造法 | |
| JPH11302178A (ja) | 脂肪肝予防及び治療剤 | |
| KR20030095197A (ko) | 패혈증의 치료 방법 | |
| AU613734B2 (en) | Method for treating hyperuricemia | |
| JPS60208914A (ja) | 肝障害の予防、治療剤 | |
| US4555510A (en) | Therapeutic agent for hypertension |